BIMZELX 160 MG/ML AUTOINJECTOR
FDA nonproprietary name: bimekizumab
For 1 mL
Pharmacies pay
$8,035.07 – $8,112.59 filed
1 × $8,035.07333 to $8,112.5853 per ML (the 2 NDCs differ)
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$7,257.94 filed
1 × $7,257.94095 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.89× – 0.90× estimated
Medicare paid between 0.89× and 0.90× what pharmacies pay, depending on the NDC.
Part D averages every strength and form sold under “Bimzelx Autoinjector” / “Bimekizumab-Bkzx” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-01-01, 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$9,245.33 – $9,334.48 estimated
NADAC for the pack + 15% + $5.00 fee per fill
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-01-01, 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
BIMZELX 160 MG/ML AUTOINJECTOR is how the CMS NADAC file names this product. The FDA NDC Directory lists it as bimekizumab, under the trade name “Bimzelx”.
FDA gives its dosage form as injection, solution and its route as subcutaneous.
The labeler, the company named on the label, is UCB, Inc.
FDA lists no Established Pharmacologic Class for it.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $8,035.07 – $8,112.59 for 1 mL, depending on the NDC ($8,035.07333 to $8,112.5853 per ML), by the CMS NADAC file of 2026-10-14; those prices took effect between 2026-01-01 and 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 4, carried forward from the previous file; 5, calculated based on package size.
The NADAC of 1 of these 2 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-01-01. The file is new; the price is not.
What NADAC measures · NADAC explanation codes · Carried-forward prices
All 2 NDCs
- 50474-0781-84 · UCB, Inc. · $8,035.07333 per ML · eff. 2026-09-23 filed
- 50474-0781-85 · UCB, Inc. · $8,112.5853 per ML · eff. 2026-01-01 filed carried forward
Other strengths, forms and brands
1 other product in the NADAC file shares the FDA nonproprietary name bimekizumab with BIMZELX 160 MG/ML AUTOINJECTOR.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| BIMZELX 160 MG/ML AUTOINJECTOR this page | $8,035.07333 to $8,112.5853 per ML filed | $7,257.94095 per ML filed |
| BIMZELX 320 MG/2 ML AUTOINJECT | $8,016.03643 per ML filed | $7,257.94095 per ML filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
What Medicare paid
Medicare Part D paid $7,257.94 for 1 mL, at an average of $7,257.94095 per ML in 2024 (2024-01-01 to 2024-12-31) for “Bimzelx Autoinjector” and “Bimekizumab-Bkzx”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 5,294 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
- Which NDC (the 11-digit number on the package) is this? Pharmacies pay $8,035.07333 to $8,112.5853 per ML for this product, depending on the NDC.
- How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for BIMZELX 160 MG/ML AUTOINJECTOR labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Bimzelx Autoinjector / Bimekizumab-Bkzx: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
- Why does this page start at 1 mL?
- The FDA package descriptions of this product’s NDCs give different amounts (1 mL, 2 mL). So the card starts at 1 ML; change it to match your prescription.